Published in Blood on October 19, 2006
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood (2011) 1.33
Platelet adhesion under flow. Microcirculation (2009) 1.31
ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. Blood (2012) 1.31
Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the framingham offspring study. Circulation (2008) 1.29
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost (2008) 1.07
Conformational activation of ADAMTS13. Proc Natl Acad Sci U S A (2014) 1.01
Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Proc Natl Acad Sci U S A (2011) 0.98
The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood (2010) 0.87
The role of the ADAMTS13 cysteine-rich domain in VWF binding and proteolysis. Blood (2015) 0.85
Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost (2007) 0.84
Clinical measurement of von Willebrand factor by fluorescence correlation spectroscopy. Clin Chem (2012) 0.82
ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. Diabetes (2013) 0.81
Von Willebrand factor antigen predicts response to double dose of aspirin and clopidogrel by PFA-100 in patients undergoing primary angioplasty for ST elevation myocardial infarction. ScientificWorldJournal (2013) 0.78
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. EBioMedicine (2015) 0.76
A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J Biol Chem (2017) 0.75
Regulation of VWF expression, and secretion in health and disease. Curr Opin Hematol (2016) 0.75
Plasma von Willebrand factor level is transiently elevated in a rat model of acute myocardial infarction. Exp Ther Med (2015) 0.75
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet (2011) 4.27
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA (2007) 3.50
Estrogen plus progestin and risk of venous thrombosis. JAMA (2004) 3.46
Risk assessment for recurrent venous thrombosis. Lancet (2010) 3.31
Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med (2006) 3.13
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet (2003) 2.98
Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA (2009) 2.85
Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med (2006) 2.75
Gene variants associated with deep vein thrombosis. JAMA (2008) 2.74
Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology (2006) 2.62
Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ (2013) 2.45
Hypoglycemia is associated with intensive care unit mortality. Crit Care Med (2010) 2.41
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol (2003) 2.40
Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol (2009) 2.37
Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev (2014) 2.28
Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med (2009) 2.26
Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med (2009) 2.16
Turbid plasma donations in whole blood donors: fat chance? Transfusion (2011) 2.15
Risks of oral anticoagulant therapy with increasing age. Arch Intern Med (2005) 2.06
Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med (2004) 2.00
Is an EMA review on hormonal contraception and thrombosis needed? BMJ (2013) 1.94
Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol (2008) 1.93
Essential role of the disintegrin-like domain in ADAMTS13 function. Blood (2009) 1.86
Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem (2006) 1.81
Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost (2003) 1.80
High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood (2011) 1.78
ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem (2005) 1.76
Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol (2004) 1.72
Multiple SNP testing improves risk prediction of first venous thrombosis. Blood (2012) 1.70
Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA (2004) 1.70
Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol (2004) 1.69
Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol (2007) 1.61
Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg (2013) 1.57
Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology (2004) 1.57
Influence of dietary vitamin K intake on subtherapeutic oral anticoagulant therapy. Br J Haematol (2010) 1.55
Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood (2006) 1.52
A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF. Blood (2009) 1.51
The effect of flight-related behaviour on the risk of venous thrombosis after air travel. Br J Haematol (2008) 1.50
Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med (2006) 1.50
Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol (2008) 1.49
The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood (2013) 1.47
Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol (2006) 1.47
Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood (2005) 1.46
Subtherapeutic oral anticoagulant therapy: frequency and risk factors. Thromb Haemost (2009) 1.46
Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem (2002) 1.45
Bleeding in carriers of hemophilia. Blood (2006) 1.41
Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol (2002) 1.41
Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial. Catheter Cardiovasc Interv (2014) 1.40
Prothrombotic gene variation in patients with large and small vessel disease. Neuroepidemiology (2008) 1.40
Fluid loss does not explain coagulation activation during air travel. Thromb Haemost (2008) 1.38
Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood (2004) 1.36
Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood (2011) 1.33
Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood (2005) 1.30
An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood (2009) 1.27
Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med (2006) 1.27
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics (2009) 1.25
N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood (2007) 1.24
The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol (2007) 1.24
Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA (2002) 1.23
Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol (2002) 1.22
Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke (2002) 1.21
A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med (2005) 1.20
Reduced body weight and increased postimplantation fetal death in tyrosylprotein sulfotransferase-1-deficient mice. J Biol Chem (2002) 1.20
Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood (2010) 1.17
Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol (2009) 1.17
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 1.16
Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol (2010) 1.16
Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica (2009) 1.15
Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol (2003) 1.14
Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol (2005) 1.12
Quantification of bias in direct effects estimates due to different types of measurement error in the mediator. Epidemiology (2012) 1.11
Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol (2011) 1.10
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood (2004) 1.10
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (2011) 1.07
Prevalence of colonisation with group B Streptococci in pregnant women of a multi-ethnic population in The Netherlands. Eur J Obstet Gynecol Reprod Biol (2005) 1.07
No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med (2007) 1.06
Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis. Thromb Haemost (2005) 1.06
Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. Europace (2013) 1.05
The relationship between exercise and risk of venous thrombosis in elderly people. J Am Geriatr Soc (2008) 1.05